Blume Capital Management’s Wave Life Sciences WVE Stock Holding History

Blume Capital Management’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-30	Closed	–	–	241
2020 Q3	$0	Buy	+30	New	+$329	﹤0.01%	234

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blume Capital Management's WVE Position: Q4 2020 in Review

Blume Capital Management sold out of Wave Life Sciences (WVE) in Q4 2020, closing a stake of 30 shares.

Blume Capital Management first reported a position in WVE in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 108 funds tracked by Wall St. Rank hold WVE as of Q4 2020.

Blume Capital Management reported no remaining Wave Life Sciences position as of Q4 2020 after selling out during the quarter.
Blume Capital Management sold 30 Wave Life Sciences shares in Q4 2020.
Blume Capital Management first reported a position in Wave Life Sciences in Q3 2020 and held it in 1 quarter.
Blume Capital Management's Wave Life Sciences position peaked at $0 in Q3 2020.
108 funds tracked by Wall St. Rank held Wave Life Sciences as of Q4 2020.

Based on Blume Capital Management's 13F filing for Q4 2020, filed 9 Feb 2021.